PipelineReview.com12h
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
BOSTON, MA, USA I 11, 2024 I Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
PipelineReview.com12h
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway ...
PipelineReview.com12h
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
WILMINGTON, DE, USA I 11, 2024 I Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) ...
PipelineReview.com13h
Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 Antibody
TOKYO, USA & NOVI, MI, USA & DÜSSELDORF, Germany I 11, 2024 I Asahi Kasei Pharma has taken another step in its transformation into a global ...
PipelineReview.com13h
Expression Therapeutics Announces Promising Phase 1 Results for Groundbreaking Hemophilia A Gene Therapy at ASH
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...
PipelineReview.com13h
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition
Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...
PipelineReview.com13h
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
SAN DIEGO, CA, USA I 11, 2024 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...
PipelineReview.com17h
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease ...
PipelineReview.com19h
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
COPENHAGEN, Denmark I 10, 2024 IZealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery ...
PipelineReview.com20h
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM, Sweden I 10, 2024 I Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...
PipelineReview.com20h
Huonslab Announces Enrollment and Administration of First Patient in Phase 1 Pivotal Study for Hydizyme™ (rHuPH20)
PANGYO, South Korea I 10, 2024 I Huonslab, a subsidiary of Huons Global (KOSDAQ: 084110), announced today the successful enrollment and ...
PipelineReview.com1d
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...